Disturbed expression of type 1 iodothyronine deiodinase splice variants in human renal cancer

Thyroid

Volumn 19, Issue 10, 2009, Pages 1105-1113

  Piekielko Witkowska, Agnieszka ^a   Master, Adam ^a   Wojcicka, Anna ^a   Boguslawska, Joanna ^a   Brozda, Izabela ^a   Tanski, Zbigniew ^b   Nauman, Alicja ^a  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b Province Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RIBONUCLEOPROTEIN; RIBONUCLEOPROTEIN A1; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IODOTHYRONINE DEIODINASE 1 GENE; KIDNEY CANCER; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SPLICING;

CLONING, MOLECULAR; DATABASES, GENETIC; DNA PRIMERS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IODIDE PEROXIDASE; KIDNEY NEOPLASMS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70350655750     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0284     Document Type: Article

References (36)

1. Jakobs TC, Koehler MR, Schmutzler C, Glaser F, Schmid M, Kö hrle J 1997 Structure of the human type I iodothyronine 50-deiodinase gene and localization to chromosome 1p32- p33. Genomics 42:361-363.
2. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89.
3. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A 2002 Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 23:25-33.
4. Puzianowska-Kuznicka M, Nauman A, Madej A, Tanski Z, Cheng S, Nauman J 2000 Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett 155:145-152.
5. Qi JS, Yuan Y, Desai-Yajnik V, Samuels HH 1999 Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol Cell Biol 19:864-872.
6. Dinda S, Sanchez A, Moudgil V 2002 Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 21:761-768.
7. de Souza Meyer EL, Dora JM, Wagner MS, Maia AL 2005 Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. Clin Endocrinol (Oxf ) 62:672-678.
8. Ambroziak M, Pachucki J, Stachlewska-Nasfeter E, Nauman J, Nauman A 2005 Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1=nkx2-1 and pax-8 transcription factor genes in papillary thyroid cancer. Thyroid 15:1137-1146.
9. Arnaldi LA, Borra RC, Maciel RM, Cerutti JM 2005 Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 15:210-221.
10. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent pro- files. Proc Natl Acad Sci USA 98:15044-15049.
11. Kö hrle J, Oertel M, Hoang-Vu C, Schnieders F, Brabant G 1993 Type I 50-Deiodinase-a marker for differentiated thyroid carcinoma? Exp Clin Endocrinol 101:60-72.
12. Garcia-Solis P, Aceves C 2003 50Deiodinase in two breast cancer cell lines: effect of triiodothyronine, isoproterenol and retinoids. Mol Cell Endocrinol 201:25-31.
13. Wassen F, Peeters R, Kuiper GGJM, Visser TJ 2002 Type I iodothyronine deiodinase splice variants in human liver. Proceedings of 74th Annual Meeting of the American Thyroid Association, Los Angeles, CA, p 208 (Abstract no. 198).
14. Wassen FW, Klootwijk W, Kaptein E, Duncker DJ, Visser TJ, Kuiper GG 2004 Characteristics and thyroid state-dependent regulation of iodothyronine deiodinases in pigs. Endocrinology 145:4251-4263.
15. Srebrow A, Kornblihtt AR 2006 The connection between splicing and cancer. J Cell Sci 119:2635-2641.
16. Cáceres JF, Stamm S, Helfman DM, Krainer AR 1994 Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science 265:1706-1709.
17. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS 2007 Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol 9:47-56.
18. Young AN, Dale J, Yin-Goen Q, Harris WB, Petros JA, Datta MW, Wang MD, Marshall FF, Amin MB 2006 Current trends in molecular classification of adult renal tumors. Urology 67:873-880.
19. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD 2002 Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 100:30-36.
20. Hara I, Miyake H, Yamanaka K, Hara S, Arakawa S, Kamidono S 1999 Expression of CD44 adhesion molecules in nonpapillary renal cell carcinoma and normal kidneys. Urology 54:562-566.
21. Yang K, Lindblad P, Egevad L, Hemminki K 1999 Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas. Cancer Lett 141:1-8.
22. Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ, Dahiya R 2003 The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma. Clin Cancer Res 9:2121-2132.
23. Pachucki J, Ambroziak M, Tanski Z, Luczak J, Nauman J, Nauman A 2001 Type I 50-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest 24:253-261.
24. Grignon DJ, Che M 2005 Clear cell renal cell carcinoma. Clin Lab Med 25:305-316.
25. Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais- Bird J, Madden R, Paquet ER, Koh C, Venables JP, Prinos P, Jilaveanu-Pelmus M, Wellinger R, Rancourt C, Chabot B, Abou Elela S 2008 Multiple alternative splicing markers for ovarian cancer. Cancer Res 68:657-663.
26. Brinkman BM 2004 Splice variants as cancer biomarkers. Clin Biochem 37:584-594.
27. McGlincy NJ, Smith CW 2008 Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? Trends Biochem Sci 33:385-393.
28. Lareau LF, Brooks AN, Soergel DA, Meng Q, Brenner SE 2007 The coupling of alternative splicing and nonsensemediated mRNA decay. Adv Exp Med Biol 623:190-211.
29. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC 2004 Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet 36:1073-1078.
30. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR 2005 Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115:2524-2533.
31. Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J, Durant C, Ferrucci L, Melzer D, Saravanan P, Visser TJ, Ceresini G, Hattersley AT, Vaidya B, Dayan CM, Frayling TM 2008 A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab 93:3075-3081.
32. Cáceres JF, Kornblihtt AR 2002 Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18:186-193.
33. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR 2007 The gene encoding the splicing factor SF2=ASF is a proto-oncogene. Nat Struct Mol Biol 14:185-193.
34. Hanamura A, Cáceres JF, Mayeda A, Franza BR Jr., Krainer AR 1998 Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 4:430-444.
35. Toyoda N, Berry MJ, Harney JW, Larsen PR 1995 Topological analysis of the integral membrane protein, type 1 iodothyronine deiodinase (DIO1). J Biol Chem 270:12310-12318.
36. Toyoda N, Kaptein E, Berry MJ, Harney JW, Larsen PR, Visser TJ 1997 Structure-activity relationships for thyroid hormone deiodination by mammalian type I iodothyronine deiodinases. Endocrinology 138:213-219.